The Food and Drug Administration (FDA) took another step forward in its efforts toward pediatric drug studies and labeling. On July 7 it issued guidelines defining the type and scope of studies companies must conduct to receive six months of market exclusivity for a product.

In May, the FDA issued a list of more than 500 drugs that need pediatric studies and labeling. The new guidelines describe how to use the list and how to obtain market exclusivity.

This content is only available via PDF.
You do not currently have access to this content.